Sökning: onr:"swepub:oai:DiVA.org:uu-374491" > Effect of apixaban ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04240naa a2200505 4500 | |
001 | oai:DiVA.org:uu-374491 | |
003 | SwePub | |
008 | 190121s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3744912 URI |
024 | 7 | a https://doi.org/10.1136/heartjnl-2018-3133512 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Christersson, Christinau Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)chchr086 |
245 | 1 0 | a Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. |
264 | c 2018-09-12 | |
264 | 1 | b BMJ,c 2019 |
338 | a electronic2 rdacarrier | |
520 | a OBJECTIVES: Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF).METHODS: The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial included 4850 patients with AF randomised to treatment with apixaban or warfarin. Sixty per cent of patients used vitamin K antagonist (VKA) within 7 days before randomisation. Prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand (sCD40L) and von Willebrand factor (vWF) antigen were analysed at randomisation and after 2 months of study treatment.RESULTS: In patients not on VKA treatment at randomisation, F1+2 and D-dimer levels were decreased by 25% and 23%, respectively, with apixaban, and by 59% and 38%, respectively, with warfarin (p<0.0001 for treatment differences for both). In patients on VKA at randomisation, F1+2 and D-dimer levels increased by 41% and 10%, respectively, with apixaban and decreased by 37% and 11%, respectively, with warfarin (p<0.0001 for treatment differences for both). sCD40L levels were slightly increased at 2 months, regardless of VKA or randomised treatment. Apixaban and warfarin also both reduced vWF antigen regardless of VKA treatment. The efficacy (stroke) and safety (bleeding) of apixaban compared with warfarin was similar irrespectively of biomarker levels at 2 months.CONCLUSIONS: Treatment with apixaban compared with warfarin for stroke prevention in patients with AF was associated with less reduction in thrombin generation and fibrin turnover. This effect of apixaban could contribute to the clinical results where apixaban was superior to warfarin both in stroke prevention and in reducing bleeding risk.TRIAL REGISTRATION NUMBER: NCT00412984. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a atrial fibrillation | |
700 | 1 | a Wallentin, Lars,d 1943-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)larswall |
700 | 1 | a Andersson, Ulrikau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)ulran224 |
700 | 1 | a Alexander, John H4 aut |
700 | 1 | a Alings, Marco4 aut |
700 | 1 | a De Caterina, Raffaele4 aut |
700 | 1 | a Gersh, Bernard J4 aut |
700 | 1 | a Granger, Christopher B4 aut |
700 | 1 | a Halvorsen, Sigrun4 aut |
700 | 1 | a Hanna, Michael4 aut |
700 | 1 | a Huber, Kurt4 aut |
700 | 1 | a Hylek, Elaine M4 aut |
700 | 1 | a Lopes, Renato D4 aut |
700 | 1 | a Oh, Byung-Hee4 aut |
700 | 1 | a Siegbahn, Agneta,d 1947-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)agsie424 |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t Heartd : BMJg 105:3, s. 235-242q 105:3<235-242x 1355-6037x 1468-201X |
856 | 4 | u https://doi.org/10.1136/heartjnl-2018-313351y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1281166/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://heart.bmj.com/content/heartjnl/105/3/235.full.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374491 |
856 | 4 8 | u https://doi.org/10.1136/heartjnl-2018-313351 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.